pharma

Bone Biologics Corporation (NASDAQ:BBLG) stock is trading higher on Friday, with a session volume of 17.22 million compared to the average volume of 38.795K as per data from Benzinga Pro. The company filed a patent application with the U.S. Patent and Trademark Office (USPTO) for its preclinical...

Viking Therapeutics, Inc. (NASDAQ:VKTX) on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in oral and...

Amgen Inc (NASDAQ:AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, MariTide demonstrated up to...

Hims & Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant. Check out the current price of HIMS...

Donald Trump Jr. has joined billionaire entrepreneur Mark Cuban in publicly voicing disapproval of Sen. Elizabeth Warren (D-Mass.)’s approach to healthcare pricing. Despite their political differences, Trump Jr. and Cuban found a common point of contention in Warren’s healthcare pricing...

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices. What Happened: The clash, unfolding as of Friday, has reignited discussions on Pharmacy Benefit Managers (...

Billionaire investor and the CEO of Pershing Square, Bill Ackman, flagged the contribution of various subsidies to the mounting U.S. debt and appreciated President Donald Trump for proposing an order to cut the drug prices, quoting his earlier suggestion. What Happened: In an X post, Ackman...

Roche Holdings AG (OTC:RHHBY) has revealed a $50 billion investment plan centering on manufacturing and research in the U.S., indicating a strategic change as potential drug tariffs loom. What Happened: The Swiss pharmaceutical giant will establish new and expanded facilities across Indiana,...

Even as President Donald Trump paused the reciprocal tariffs for 90 days on Wednesday, he later confirmed in a conversation with reporters at his Oval Office that pharmaceutical companies would face tariffs. What Happened: The rally in pharma stocks was short-lived after the stocks reversed course...

Shares of Century Therapeutics Inc (NASDAQ:IPSC) zoomed by 20.74% to $1.63 per share on Wednesday, which is the highest price move in nearly a month since Oct. 1. The shares also rose the most in over 11 months since Dec. 6, 2023, in a single day. Also read: Trump’s Tariff Threat To Canada...

In a recent conversation on The Joe Rogan Experience, Elon Musk and Joe Rogan delivered a sharp critique of the pharmaceutical industry, bashing its history of prioritizing profit over public safety. Their discussion not only touched on well-known scandals like OxyContin and Vioxx but also ventured...

As April comes to a close, it’s time to compile the rankings for the top-performing sector and industry exchange-traded funds of the month. Taking a broader look at the stock market, the S&P 500 Index, represented by the SPDR S&P 500 ETF Trust (NYSE:SPY), finished April on a downturn...

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. But, in a post-pandemic world, Pfizer and Moderna shares lost about 30% of their respective value over the...

Hedge funds are steering clear of the booming artificial intelligence (AI) market and other technology stocks that have led the market rally over the past year. Instead, they are placing their bets on the healthcare sector, revealing a calculated move towards stability and value. According to the...

With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned to fighting cancer, the one battle that pharma never seems to win. Moderna ended 2023 by...